INDUSTRY AND ACADEMIC ADVANCES IN THIS EXCITING AND RAPIDLY DEVELOPING FIELD

Immuno-Oncology SUMMIT EUROPE 2019

CAMBRIDGE HEALTHTECH INSTITUTE’S FOURTH ANNUAL

2019 CONFERENCE PROGRAMMES

18-19 MARCH

- Immunomodulatory Approaches
- Biomarkers for Immuno-Oncology

20-21 MARCH

- Combination Immunotherapy
- Oncolytic Virus Immunotherapy

21-22 MARCH

- Adoptive T-Cell Therapy
- Preclinical & Translational Immuno-Oncology

4 SHORT COURSES

MONDAY 18 MARCH | 9:30 - 12:30
The Tumour Microenvironment and Response to Cancer Immunotherapy

Next Generation Immunotherapies

THURSDAY 21 MARCH | 18:30 - 21:30
Managing the Challenges of Bioassays for Immuno-Oncology

T Cell Therapies: Current Field, Challenges and Future Directions

REGISTER EARLY FOR MAXIMUM SAVINGS

2019 CONFERENCE PROGRAMMES

18-19 MARCH

- Immunomodulatory Approaches
- Biomarkers for Immuno-Oncology

20-21 MARCH

- Combination Immunotherapy
- Oncolytic Virus Immunotherapy

21-22 MARCH

- Adoptive T-Cell Therapy
- Preclinical & Translational Immuno-Oncology

4 SHORT COURSES

MONDAY 18 MARCH | 9:30 - 12:30
The Tumour Microenvironment and Response to Cancer Immunotherapy

Next Generation Immunotherapies

THURSDAY 21 MARCH | 18:30 - 21:30
Managing the Challenges of Bioassays for Immuno-Oncology

T Cell Therapies: Current Field, Challenges and Future Directions

REGISTER EARLY FOR MAXIMUM SAVINGS

FEATURED SPEAKERS

Frank Tufaro, PhD, CEO, DNAtrix, Inc.
Roy Baynes, MD, Senior Vice President, Global Clinical Development & CMO, Merck Research Labs
Ed Schuuring, PhD, Professor & Head, Molecular Pathology, University Medical Center Groningen
Sara Colombetti, PhD, Head of Oncology Discovery Pharmacology, Pharmacology, Roche Innovation Center Zurich
Christian Klein, PhD, Distinguished Scientist & Head, Oncology Programs, Roche Innovation Center Zurich
Andre Choulika Chairman, CEO, Cellectis, Inc.

CORPORATE SPONSORS

Immuno-OncologyEurope.com
Dear Colleague

Following our year-on-year success, CHI is excited about presenting a much-enlarged SIX-TRACK Immuno-Oncology Summit Europe for March 2019. The track on Immuno-modulatory Approaches examines the multiple factors that interact in the tumour microenvironment and presents case studies from the field for stimulating the immune response and overcoming inhibitory factors. The Combination Immunotherapy conference track presents successful results with combinations ranging from double immunotherapy to immune checkpoint inhibitors combined with conventional cancer therapy. Important factors such as predictive biomarkers, therapeutic mechanisms, and reducing toxicity are all addressed.

Following the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

The track on Combination Immunotherapy follows the recent FDA approval of two CAR-T therapies, interest in Adoptive T-Cell Therapy has intensified. At this event experts present.

Our Inaugural Oncolytic Virus Immunotherapy conference showcases this approach as a valuable therapeutic. It brings together leading industry and academic leaders to discuss the critical steps needed to accelerate oncolytic virus immunotherapy into the clinic. The inaugural Preclinical and Translational Immuno-Oncology conference delves into the advantages and disadvantages of a variety of immune system models and presents strategies employed to help translate positive results to clinical trials.

Don’t miss the short courses on highly relevant topics. We continue to hold this event in London’s Canary Wharf, a thriving, modern and up-beat part of London that has worked very well for us in recent years.

Nicole Lyssom, PhD
Senior Conference Director
Cambridge Healthtech Institute

SHORT COURSES*

MONDAY 18 MARCH
9:30 – 12:30

SC1: The Tumour Microenvironment and Response to Cancer Immunotherapy
Stephen A. Beers, PhD, Professor of Immunology and Immunotherapy, Centre for Cancer Immunology, University of Southampton

The tumour microenvironment (TME) is a complex, dynamic environment in which the behaviour of tumour cells alters in response to cues from the extracellular matrix (ECM), cytokines, immune cells, and stromal cells. As well as propagating tumour growth and spread, the TME may also influence the response to immunotherapy. For example, stromal cells such as fibroblasts may drive cancer growth through production of TGFβ whilst macrophages display immunosuppressive and tumour promoting properties, through driving tumour cell proliferation and survival. In this short-course we will discuss the nature of the TME and the multiple ways in which it promotes an immunosuppressive environment. Opportunities to alter the TME in order to more effectively deliver immunotherapy will also be discussed.

SC2: Next Generation Immunotherapies
A short course featuring the exciting approaches being used by today’s immune-oncology scientists. You will learn about current successes and future potential, and how the leaders in the field overcame the challenges encountered.

1. Bispecific Antibodies: Formats, Considerations, Developability and Opportunities
Laura von Schanz, Director, Alligator Biosciences

2. Immuno-cytokines: New Formats and New Strategies
Dario Neill, PhD, Professor, Biomacromolecules, Chemistry and Applied Biosciences, ETH Zurich

3. Cellular Therapies: Current Successes and New Directions
Ryan McCoy, Lead Technical Scientist, Cell and Gene Therapy, Catapult

4. The Yin and the Yang of the Innate Immune System in Cancer Therapy
R.J. Tesi, MD, CEO and CMO, Inmune Bio

5. In vitro/ex vivo Models and Adapting in vivo Models to Study Immunology–Oncology and Antibody Functions
Sofia N. Karagiannis, BA, MS, PhD, Reader, Translational Cancer Immunology, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences

SC3: Managing the Challenges of Bioassays for Immunology–Oncology
Sophie Patijn, CTO, ImmunoXperts

Aven Gallimore, DPhil, Professor, Immunology, Infection and Immunity, Cardiff University

The tumour microenvironment (TME) is a complex, dynamic environment in which the behaviour of tumour cells alters in response to cues from the extracellular matrix (ECM), cytokines, immune cells, and stromal cells. As well as propagating tumour growth and spread, the TME may also influence the response to immunotherapy. For example, stromal cells such as fibroblasts may drive cancer growth through production of TGFβ whilst macrophages display immunosuppressive and tumour promoting properties, through driving tumour cell proliferation and survival. In this short-course we will discuss the nature of the TME and the multiple ways in which it promotes an immunosuppressive environment. Opportunities to alter the TME in order to more effectively deliver immunotherapy will also be discussed.

Part One: Bioassays for Non-Cellular Products
This part will present experiences and data regarding bioassays for immune-modulatory antibodies and combination approaches. It will include the challenges with understanding the question you want answered and designing and interpreting an appropriate assay, as well as translating the results and managing expectations. It will examine prediction versus documenting MTA, what the bioassay does, what it is measuring, what it means and its value. Technical challenges will be addressed and case studies with data will be provided.

Part Two: Bioassays for Cellular Products
This second part will focus on bioassays used to support clinical development of cell-based immunotherapies, specifically CAR or TCR T-cell therapies. It will address the challenges linked with the choice/design of assays for toxicity and potency assessment. It will focus on risk assessment, particularly incoming material and genetic engineering steps; assessment of off-target effects; assessment of tumorigenicity with a focus on viral vector insertion; predictivity of current in vivo tumorigenicity assays, and animal models for safety and toxicity. Regarding efficacy and potency assays, it will focus on recapitulating a mode of action in animal and in vitro models; in vitro assays, and technical challenges.

Please see website for more details.

*Separate registration required

Cambridge Healthtech Institute
Senior Conference Director
Nicole Lyscom, PhD

www.immuno-oncology.com
By protecting transmembrane TNF function, INB03 does not cause tumour regression after Treg-depletion is highly variable. It is becoming found that while depleting Treg results in significant immune activation, compartment for therapeutic gain.

In this talk I will discuss the role of regulatory T cells in the context where they help create an immunosuppressive niche. We have Foxp3+ regulatory T cells (Treg) often accumulate in solid tumours with increased MDSC should reverse CPI. A predictor of resistance to checkpoint inhibitors is the number targeted 4-1BBL fusion proteins.

In all the talk I will discuss the use of FcγR humanized mouse models as a platform for engineering novel immune activators such as a TIL-targeted TCR-BASED BISPECIFICS.

I will also discuss preclinical development of these and of XmAb24306, a bispecific antibody therapy approaches. These offer opportunities to treat patients with immunologically cold tumours will be explored. Finally, subsequent candidates emerging from the pipeline will be discussed and will illustrate the potential of the immTAC platform.

Focus on Fc Engagement for Effective Targeting

14:55 The Sting in the Tail of Antibody Therapy

Stephen A. Bears, PhD, Professor of Immunology and Immunotherapy, Centre for Cancer Immunology, University of Southampton

INHIBITORS AND ANTAGONISTS

16:15 Fc-Optimized Immuno-Modulatory Antibodies

Rohit Chahal, PhD, Assistant Professor, Immuno-Modulatory, Weizmann Institute of Science

I will present an overview of FcγR-dependent mechanisms of immunomodulatory Abs, while focusing on case study of Fc-engineered anti-CD40 agonistic Abs and approaches for increasing their therapeutic window. I will describe the use of FcγR humanized mouse models to assess the efficacy and toxicity of human immunomodulatory Abs, while explaining the challenges overcome while translating findings in mice into human IgG-based therapies.

16:45 ATOR-1017 - A Tumor Directed Fc-Receptor Cross Linking Dependent 4-1BB Agonistic Antibody

Kathrin Ertl-Smith, PhD, Senior Scientist, Preclinical Development, Alligator Bioscience

ATOR-1017 is a FcγR cross-linking dependent 4-1BB agonistic antibody. ATOR-1017 was designed for an optimal efficacy and improved safety, by combining the IgG4 format that mediates a potent FcγR cross-linking with a unique binding epitope on 4-1BB. The immune activation will be directed to tumors co-expressing both specific FcγRs and 4-1BB, potential biomarkers for patient and tumor selection indication. Clinical studies with ATOR-1017 are ongoing.

Conferences Registration

12:30 Conference Registration

OVERCOMING LIMITATIONS OF CHECKPOINT INHIBITORS AND ANTAGONISTS

13:30 Organizer’s Welcome Remarks

Nicole Lyssom, PhD, Senior Conference Director, Cambridge Healthtech Institute

13:35 Chairperson’s Welcome Remarks

Dario Neri, PhD, Professor, Biocromacromolecules, Chemistry and Applied Biosciences, ETH Zürich

13:45 KEYNOTE: Targeting Regulatory T Cells in Cancer: Means and Mechanisms

Sergi A. Ovejero, PhD, Professor, University College London Cancer Institute

Regulatory T cells have a recognised and critical role in the maintenance of immune homeostasis in mice and man. In this talk I will discuss the role of regulatory T cells in the context of cancer, as well as new and old strategies aiming to target this compartment for therapeutic gain.

14:15 Targeting Tregs to Manipulate the Tumour Vasculature and Enhance T-Cell Tumour Targeting

Awen Gallimore, PhD, Professor of Immunology, Infection and Immunity, Cardiff University

Fas+/regulatory T cells (Treg) often accumulate in solid tumours where they help create an immunosuppressive niche. Many groups have found that while depleting Treg results in significant immune activation, tumour regression after Treg depletion is highly variable. It is becoming increasingly clear that features defining the tumour microenvironment impact on the ability of the immune system to attack tumours and represent additional targets through which the success of immunotherapy can be maximized.

14:45 Targeting Myeloid-Derived Suppressor Cells to Overcome Resistance to Checkpoint Inhibitors

R. J. Tesi, MD, CEO and CMO, MimiBio

A predictor of resistance to checkpoint inhibitors is the number of MDSC in the patient’s blood. Combination immunotherapy with INB03 in patients with increased MDSC should reverse CPI resistance. INB03, a second-generation TNF inhibitor targets soluble TNF to decrease MDSC while improving NKC cytotoxic and T cell recruitment. By protecting transmembrane TNF function, INB03 does not cause immunosuppression, a known off target effect of currently approved non-selective TNF inhibitors.

15:15 Networking Refresh Break

18:00 Registration and Morning Coffee

8:30 Chairperson’s Opening Remarks

Sophia N. Karagiannis, BA, MS, PhD, Reader, Translational Cancer Immunology, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London

18:30 Featured Presentation

Tumor-Targeted 4-1BBL Fusion Proteins for Combination with T-Cell Specific Bispecific Antibodies in Cancer Immunotherapy

Chintan K. Doshi, PhD, Distinguished Scientific Head, Cancer Programs, ImmunoTherapy Discovery, Roche Pharmaceutical Research and Early Development, Roche Innovation Center Zurich

The presentation will focus on data supporting the combination of T-cell bispecific antibodies with tumor-targeted 4-1BBL fusion proteins.
15:45 Predictive and Prognostic Biomarkers for Immunotherapy and Combination Therapy

Kathleen M. Mahoney, MD, PhD, Instructor of Medicine, Medicine, Hematology-Oncology, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute

Many clinical trials have investigated the toxicity and efficacy of combining PD-1 pathway blockade with other therapies. Yet few randomized Phase II studies involving immune checkpoints have been designed to develop predictive biomarkers for these therapies. Biomarker-driven early phase trials are needed for designing Phase III trials to prospectively validate (protein or gene signature-based) biomarkers for monotherapy or combination immunotherapy, which is necessary for expediting patients’ access of these therapeutic options.

16:15 Next-Generation Biomarkers for the Era of Combination Immunotherapy

Mohini Rajasagi, MD, PhD, Director Translational Oncology and Clinical Biomarkers, Oncology Research Clinical, Merck Sharp and Dohme (MED)

Immune checkpoint blockade therapies are revolutionizing the standard of care for cancer treatment. However, not all patients respond to immunotherapy and even those that do, often experience toxicities. Combination approaches are the key to improving clinical response. Novel biomarkers and high-throughput technologies enable us to understand the mechanisms underlying the complex interactions between the immune system and cancer, identify predictive biomarkers for patients who will most likely benefit from current immunotherapies, avoid immune-related adverse events, mechanisms of resistance and guide future combination cancer immunotherapy.

16:45 Rapid High-Throughput Functional Selection of Neoantigens and Assessment of Their Safety

Miloscev Stojilovic, MD, Head of Technology and Innovation, Medigene AG

Neoantigens are an important class of highly specific target molecules for specific vaccine and TCR-based immunotherapies. Identification of neoantigens by next-generation sequencing and prediction of binding to the HLA alleles of a patient still leaves open the issue of actual immunogenicity and safety of neoantigen targets for therapeutic use. Medigene combines high throughput functional screening with sophisticated in silico tools to overcome several current limitations in selecting relevant neoantigens.

17:15 Talk Title to be Announced

Ama Kromminga, MD, Senior Vice President & Global Chief Scientific Officer & Managing Director at BioAgilytix Europe, BioAgilytix

Sponsored by

Biagilx

17:30 From Staining to Analysis: End-to-End Application of UltiMarker™ Kits for Multiplexed Immunoprofiling

Angela Voss, PhD, Senior Field Application Scientist, UltiMark Learn how UltiMarker multiplex IHC assays enable access to whole of UltiMapper™ Kits for Multiplexed Immuno-Profiling

Sponsored by

ULTIMARK

17:45 Welcome Reception in the Exhibit Hall with Poster Viewing

18:00 Close of Day

TUESDAY 19 MARCH

MONITORING IMMUNOTHERAPY RESPONSE

8:00 Registration and Morning Coffee

8:30 Chairperson’s Opening Remarks

Graham Pawelec, MA, PhD, FISSA, Professor of Experimental Immunology, Second Department of Internal Medicine, University of Tuebingen Clinical School, Germany; Affiliated Scientist, Cancer Solutions Program, Health Sciences North Research Institute, Canada

8:35 Aging and the Human Immune System in the Era of Immunomodulatory Antibody Therapy for Cancer: Is It All Downhill?

Graham Pawelec, MA, PhD, FISSA, Professor of Experimental Immunology, Second Department of Internal Medicine, University of Tuebingen Clinical School, Germany; Affiliated Scientist, Cancer Solutions Program, Health Sciences North Research Institute, Canada

It is “common knowledge” that the human immune system deteriorates over time, resulting in an increased frequency of and susceptibility to infectious disease, autoimmunity and cancer, and in poorer responses to vaccines in the elderly (immunosenescence). This presentation will consider the clinically highly relevant question of how aging is impacting the responses of cancer patients to immunomodulatory antibody therapy that is currently revolutionizing medical oncology (2018 Nobel Prize).

9:05 Immune-Struma-Tumor Cell Interactions in Understanding Immune Blockade Drug Response

Jin Zhu, PhD, Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai and Senai, a Mount Sinai venture

Immune cell infiltration is positively associated with immune blockade drug response in PD-L1/1 expression and stroma-cell interaction can predict PD-L1 response in bladder cancer (Wang et al, Nature Communications, 2018). Our single cell sequencing and computational modeling provide further insights into how immune stroma-tumor cell interactions can determine immune blockade drug response.

9:35 Problem Solving Roundtable Discussion

Prognostic Biomarkers for Melanoma Patients

Moderators: Melanie K. Pfister, MD, PhD, Affiliate Professor of Oncology, Consultant and Chair, Division of Hematology-Oncology, Mayo Clinic

Biomarkers to Predict Response and Toxicity to Immunotherapy

Moderators: Ramin Malekzadeh, MD, PhD, Affiliate Professor of Oncology, Consultant and Chair, Division of Hematology-Oncology, Mayo Clinic

Developing Biomarkers for Combination Therapy

Moderators: Kathleen M. Mahoney, MD, PhD, Instructor of Medicine, Medicine, Hematology-Onco, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute

The Value of Liquid Biopsy as a Non- or Minimally Invasive Alternative to Tissue Biopsy for Immunotherapy Monitoring

Moderator: Irina Nazarenko, PhD, Group Leader, Exosome and Tumor Biology, Medical Center, University of Freiburg

10:35 Coffee Break in the Exhibit Hall with Poster Viewing

11:55 Systems Approach to Cancer Immunology Biomarker Discovery

Matthew Albert, MD, PhD, Principal Scientist, Cancer Immunology, Genomics

Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration.

11:45 Applying Immune Receptor Sequencing in the Discovery and Profiling of Immunooncology ‘Living Drugs’

Jan H. Bergmann, PhD, Senior Scientist, Genomics Platform and Immune Receptor Discovery, Agency

Recent developments in sequencing technologies both on bulk and in particular the single cell level open up tremendous opportunities in functional immune receptor discovery, preclinical R&D as well as treatment monitoring in the field of immuno-oncology. Collectively, genomics technologies paired with innovative cell and molecular strategies are leveraging increased sensitivity and specificity to complement this rapidly developing therapeutic field.

12:15 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:45 Dessert Break in the Exhibit Hall with Poster Viewing

13:35 Session Break

THE MICROBIOME AND METABOLIC BIOMARKERS

14:00 Chairperson’s Remarks

Tina J. Hekken, MD, FACS, Associate Professor of Surgery, Surgery, Mayo Clinic

14:05 The Breast Tissue Microbiome, Stromal and Immune Cells in Association with Benign and Malignant Breast Disease

Tina J. Hekken, MD, FACS, Associate Professor of Surgery, Surgery, Mayo Clinic

Recent advances, as well as alterations in the immune cell composition of benign breast biopsies, encompassing both innate and adaptive immune effectors, have been described in association with future breast cancer risk. In tandem, pilot data suggests that the composition of the innate microbe of sterile obtained historically normal breast tissues is different between women who develop breast cancer and those without breast cancer. Associations between the breast tissue microbiome, microenvironment and disease state (benign versus malignant) suggest potential novel biomarkers of breast cancer risk and targets for primary prevention.

14:35 Relevance of Heterogeneous EV Populations for Liquid Biopsy as a Source of Biomarkers

Irina Nazarenko, PhD, Group Leader, Exosome and Tumor Biology, Medical Center, University of Freiburg

The need to develop better approaches allowing comprehensive molecular characterization of small, barely detectable tumor has led to the development of the “Liquid Biopsy” concept. In view on the complexity of both nucleic acid and proteins of different origins, a question of a specific impact of each of these different compartments, such as free circulating nucleic acids and extracellular vesicles on the outcome of liquid biopsy-based tests can be addressed.

15:05 Talk Title to be Announced

Lorella Di Donato, Senior Vice President & COO, Operations, Capion Bioscience

15:30 Breakfast Presentation in the Exhibit Hall with Poster Viewing

15:30 Refreshment Break in the Exhibit Hall with Poster Viewing
**16:15 A Significant Clinical Role of the Immune Biomarker sIL-2R for Cancer Patients**

Vivian Barak, PhD, Prof, Head, Immunology Lab for Tumor Diagnosis, Oncology, HADASSAH-Medical Center

sIL-2R is an Immune Biomarker and its blood levels can be used in various malignancies to:

- distinguish between Cancer patients and normal controls
- evaluate therapies effects
- provide prognosis for patients
- I will present results for patients with Breast Cancer, Melanoma-Cutaneous and Uveal, Head and Neck Cancer

**16:45 The First Biomarker-Defined Tumor Indication: FDA Approval of Pembrolizumab for MSI-High Cancer**

Kenneth Emancipator, DABP, MD, Executive Medical Director and Head of Companion Diagnostics, Translational Medicine, Merck & Co.

The program presents an overview of microsatellite instability (MSI) and mismatch repair defect (dMMR), and how it fits into the tumor immunogenicity-inflammation pathway. It reviews the history and clinical evidence for MSI and dMMR as a predictive biomarker for response to pembrolizumab. It discusses the unprecedented – and unorthodox – path to FDA approval of pembrolizumab. Finally, it discusses MSI and dMMR in the broader context of biomarkers in immuno-oncology.

**17:15 Multiplexing of Tryptophan and Its Metabolites for Patient Stratification and Monitoring in Immuno-Oncology**

Christiane Opitz, PhD, Group Leader, Brain Cancer Metabolism, German Cancer Research Center, DKFZ

Tryptophan degradation is a potent immunosuppressive mechanism regulating anti-tumor immune responses. As treatments modulating tryptophan degradation are becoming available, methods to efficiently and precisely measure tryptophan degradation are becoming increasingly relevant both for stratification of patients to treatments as well as assessment of therapeutic efficacy. We employed isobaric mass tags to develop a method that enables quantitative comparison of tryptophan degradation simultaneously in up to 11 different samples. Using this method we studied the effects of the tryptophan pathway modulator indoximod on tryptophan metabolism in human cancer and immune cells. A proof of principle study comparing tryptophan degradation in 40 glioblastoma patients to age- and sex-matched healthy controls revealed reduced levels of tryptophan and downstream tryptophan metabolites in the glioblastoma patients.

**17:30 Close of Biomarkers for Immuno-Oncology**
11:15 Bispecific Antibodies for Tumor-Directed Blockade of CD47, a Puzzlingly Explored Immune Checkpoint

Stefano Majocchi, MD, Research Scientist & Project Leader, Research Department, InnovaNova SA

CD47 is a membrane protein that is expressed on the surface of all nucleated cells. It is a ligand of several receptors, including the mannose receptor, and is involved in the immune response. When CD47 binds to these receptors, it blocks the recognition of the cell by the immune system, allowing it to escape destruction.

11:45 The Use of Bispecific Antibodies to Modulate Anti-Tumor Immune Responses

Melanie Medcalf, PhD, Senior Scientist, Drug Discovery, F-star Biotechnology Ltd

Bispecific antibodies are a type of biopharmaceutical that can target two different antigens simultaneously. They have the potential to activate the immune system against cancer cells.

12:15 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

12:45 Dessert Break in the Exhibit Hall with Poster Viewing

13:15 Session Break

MULTIPLE IMMUNOTHERAPY COMBINATIONS

14:00 Chairperson’s Remarks

Robert Wilkinson, PhD, Director, Oncology Research, MedImmune

14:05 On the Requirement to Induce Immune Modulation Prior to Combination Immunotherapy Instructor: Lessons from Mice and Men

Angus Dalgleish, MD, FRCP, FRCP(C), FRCPATH, FMedSci, Foundation Professor of Oncology, Southern General Hospital, University of Glasgow

Checkpoint inhibitors (CPIs) have revolutionized the treatment of several cancer types, however, the majority of patients do not benefit on single agents. Mouse studies show that response to CPIs do not occur unless innate immune cells are activated and other markers are reduced. IMM-101 activates innate immune responses and has been reported to enhance clinical responses to CPIs in melanoma patients.

14:35 Regulatory Challenges and Opportunities for Combination Development

Elena Spanjard, PhD, Global Head of Regulatory Affairs, Regulatory Affairs, Celldex

Efficient co-development of novel combination therapies presents significant regulatory challenges. This presentation will outline how modality-specific regulatory guidelines and expedited pathways will be reviewed, including qualifying criteria, features, and benefits.

15:05 Problem Solving Roundtable Discussions

Why Are IO-Combination Therapies Harder to Develop than Anticipated? Moderators: Alexander Eggermont, MD, PhD, Chief Medical Officer, IGM Biosciences; Daniel S. Chen, MD, PhD, Chief Medical Officer, IGM Biosciences; Johan Lantto, PhD, Project Director, Immuno-Oncology, Symphogen

Optimal Checkpoint Combinations

Moderator: Angus Dalgleish, MD, FRCP, FRCP(C), FRCPATH, FMedSci, Foundation Professor of Oncology, Southern General Hospital, University of Glasgow

The immune checkpoint inhibitors (ICIs) anti-CTLA-4 (Ipilimumab) and anti-PD1/PD-L1 ( Pembrolizumab and Nivolumab) are the basis of unprecedented development of successful combination strategies across many tumor types. Melanoma has been at the forefront of this development wherein 7 years, advanced melanoma was transformed from a lethal tumor to a one of 50% of patients.

15:40 Development and Discovery of Antibody Combinations for Cancer Immunotherapy

Johan Lantto, PhD, Project Director, Immuno-Oncology, Symphogen

Symphogen’s antibody engineering platform provides the unique capacity to activate neutrophils, our most abundant but often neglected member of the innate immune system.

16:00 Refreshment Break in the Exhibit Hall with Poster Viewing

16:30 Lessons from Melanoma and the Development of Combination Immunotherapeutics

Alexander Eggermont, MD, PhD, Professor Surgical Oncology, University Paris-Sud; Director General, Director, Gustave Roussy Comprehensive Cancer Center

The immune checkpoint inhibitors (ICIs) anti-CTLA-4 (Ipilimumab) and anti-PD1/PD-L1 (Pembrolizumab and Nivolumab) are the basis of unprecedented development of successful combination strategies across many tumor types. Melanoma has been at the forefront of this development wherein 7 years, advanced melanoma was transformed from a lethal tumor to a one of 50% of patients.

16:45 Discovery and Development of Antibody Combinations for Cancer Immunotherapy

Johan Lantto, PhD, Project Director, Immuno-Oncology, Symphogen

Symphogen’s antibody engineering platform provides the unique capacity to activate neutrophils, our most abundant but often neglected member of the innate immune system.

17:30 Safety Issues in Combinatorial Immunotherapy Trial Design

Joanna Karydas, BM, BCN, MA, DMPP, MRCP Associate Professor in Medical Oncology, Imperial College of London Science, University of Southampton

The last decade has seen a rapid paradigm shift in clinical trial design; a number of innovative approaches have accelerated the process of bringing a novel agent from lab to clinic. Development of immunooncology agents has benefited from these, however, the unique characteristics of these agents pose specific challenges when it comes to determining their safety profile. This talk will summarise the issues at play and present some solutions to them.

18:05 Networking Reception in the Exhibit Hall with Poster Viewing

19:00 Close of Day

THURSDAY 21 MARCH

NOVEL IMMUNOTHERAPY COMBINATIONS

8:00 Morning Coffee

8:30 Chairperson’s Opening Remarks

Robert Wilkinson, PhD, Chief Medical Officer, IGM Biosciences

9:00 Immuno-Oncology in the Context of the Treatment of Cancer Harding, Robert, Cancer Immunotherapy in the 21st Century

10:00 Why Are IO-Combination Therapies Harder to Develop than Anticipated? Moderators: Alexander Eggermont, MD, PhD, Chief Medical Officer, IGM Biosciences; Daniel S. Chen, MD, PhD, Chief Medical Officer, IGM Biosciences; Johan Lantto, PhD, Project Director, Immuno-Oncology, Symphogen

Optimal Checkpoint Combinations

Moderator: Angus Dalgleish, MD, FRCP, FRCP(C), FRCPATH, FMedSci, Foundation Professor of Oncology, Southern General Hospital, University of Glasgow

The immune checkpoint inhibitors (ICIs) anti-CTLA-4 (Ipilimumab) and anti-PD1/PD-L1 (Pembrolizumab and Nivolumab) are the basis of unprecedented development of successful combination strategies across many tumor types. Melanoma has been at the forefront of this development wherein 7 years, advanced melanoma was transformed from a lethal tumor to a one of 50% of patients.

10:45 Development and Discovery of Antibody Combinations for Cancer Immunotherapy

Johan Lantto, PhD, Project Director, Immuno-Oncology, Symphogen

Symphogen’s antibody engineering platform provides the unique capacity to activate neutrophils, our most abundant but often neglected member of the innate immune system.

11:30 Close of Combination Immunotherapy
intravenously to over 100 cancer patients. Tumor-Specific Immuno-Gene activating ligand FL T-3L. anti-CTLA4 antibody, membrane tethered IL-12 and the antigen presenting cell modulators that are safest and most effective when expressed within the TME: of SKV we have been able to engineer and express three potent immune containing a large genome deletion which exhibited augmented oncolytic activity is the stimulation of anti-tumor immunity. We have engineered oncologic viruses to be potent stimulators of antitumor immunity and therapeutics that are optimally active when combined with immune checkpoint inhibitor antibodies.

**ADVANCES IN CLINICAL TRIALS**

14:00 Chairperson’s Remarks
Stephen J. Russell, MD, PhD, CEG, Vyriad, Inc.

14:05 FEATURED PRESENTATION: Advancing Treatment for Brain Tumors with Oncolytic Adenoviruses
Frank Tufaro, PhD, CEG, DNAtrix, Inc.

14:20 Multi-cycle Oncolytic Adenovirus (MD-4) 4.0 Platform
Gloria Campbell-Flame, Sc. Dr., Professor, University of Bologna

14:35 Adenovirus-Mediated CD40L and 4-1BBL Gene Therapy – From Bench to Bedside
Angela Lokking, CEG, Lokon Pharma AB

15:10 Problem Solving Roundtable Discussions
Moderator: Ulrich M. Lauer, MD, Professor & Vice Chairman, Internal Medicine VIII, Medical University of Vienna; University Hospital Tübingen
• Types of oncolytic vaccinia vectors
• MODALITIES OF LOCAL AND SYSTEMIC TREATMENTS
• Resistance phenomena including complement inhibition of the oncolytic virus
• Real-time monitoring possibilities employing state of the art marker genes

The Power of Reporter Gene Imaging: The Pharmacologists Dream
Moderator: Stephen J. Russell, MD, PhD, CEG, Vyriad, Inc.

15:10 Tailoring of OV doses, routes and regimens to address the unpredictability and heterogeneity of clinical responses
Pharmacoimmunological and pharmacodynamic correlates in clinical trials Determining the impact of dose, route, method of administration, tumor histology, tumorgenic and immunomodulators

16:05 Refreshment Break in the Exhibit Hall with Poster Viewing

**ADVANCES IN CLINICAL TRIALS (CONT.)**

16:35 Oncolytic Virus Vaccines and Immune Checkpoint Inhibitors
John Bell, PhD, Senior Scientist, Center for Comparative Medicine Research, Ottawa Hospital Research Institute

17:05 Using Oncolytic Adenovirus Armed with TNFα and IL-2 to Modulate the Tumor Microenvironment for Effective T-Cell Therapy and Checkpoint Inhibition
Akseli Hemminki, MD, PhD, Founder & Chairman of the Board, TILT Biotechnologies

17:30 Sponsored Presentation (Opportunity Available)
Enjoy Lunch on Your Own

18:05 Close of Day

**TUESDAY 21 MARCH**

**MODULATING THE IMMUNE SYSTEM**

8:00 Morning Coffee
8:30 Chairperson’s Opening Remarks
Frank Tufaro, PhD, CEO, DNAtrix, Inc.

8:35 Oncolytic Viruses and Adoptive Natural Killer Cell Therapy: A Match Made in Heaven?
Ewen Alston, MD, PhD, Head, Gene and Cell Therapy Group, Division of Hematology, Medicine, Karolinska University Hospital

9:05 Using Oncolytic Adenovirus Armed with TNFα and IL-2 to Modulate the Tumor Microenvironment for Effective T-Cell Therapy and Checkpoint Inhibition
Akseli Hemminki, MD, PhD, Founder & Chairman of the Board, TILT Biotechnologies

I will talk about the observations and patient data from Advanced Therapy Access Program treated with different oncolytic viruses and share our latest results for TILT Biotechnologies lead product TILT123: TNFα and IL-2

9:35 Sponsored Presentation (Opportunity Available)
Enjoy Lunch on Your Own

10:05 Coffee Break in the Exhibit Hall with Poster Viewing

**DISCOVERING NEW OVL PLATFORMS**

10:45 Novel Potencies for Oncolytic Virotherapy
Eric Quemeneur, PharmD, PhD, CSO, Transgene Vaccinia has proven to be an efficient platform for the engineering of armed oncolytic viruses, and many Vaccinia-based products are currently in clinical development. Other potencies are also considered to generate new platforms with improved therapeutic index or biodistribution settings. In this perspective, we recently studied cowpox, pseudocowpox, adenovirus, a novel virus obtained after shuffling 4 Vaccinia strains. They display increased toxicity and stability compared to existing Vaccinia platforms.

11:15 Preclinical Development of Next-Generation Oncolytic Vaccinia Viruses for Use as Immunotherapeutics
Steve M. Thorne, CSO, Western Oncolytics Vaccinia represents a flexible backbone for use in oncologic viral vectors due to its immune activating properties and systemic delivery potential. Although several oncolytic vaccinia vectors have demonstrated this potential in a clinical setting, a next generation of viruses is needed to more effectively combine with existing IO therapies. Several approaches to developing enhanced and more effective vaccinia-based OV therapies will be discussed.

11:45 Replicating Retroviral Vectors as Targeted Immuno-Oncology Agents with Significant Clinical Therapeutic Potential and Safety Record
Douglas J. Jolly, PhD, Executive Vice President, Research & Development, Aksela Therapeutics Inc.

Toca 511 is a gammarrativiral replicating vector encoding cytotoxic deaminase which selectively infects tumor cells and converts the antifungal drug 5-flucytosine into 5-fluorouracil (5-FU) which directly kills tumor cells and stimulates antitumor immune responses. As part of clinical monitoring of Phase I clinical trials in recurrent high grade gliomas, we have performed extensive molecular analyses of patient specimens to track vector fate.

12:15 Luncheon Presentation (Sponsorship Opportunity Available)
Enjoy Lunch on Your Own

12:45 Dessert Break in the Exhibit Hall with Poster Viewing

13:30 Close of Oncolytic Virus Immunotherapy
TILs, TCRs AND GAMMA DELTA

14:30 Chairperson’s Opening Remarks

Rene Debets, PhD, Associate Professor; Laboratory of Tumor Immunology, PI, Medical Oncology, Erasmus MC-Cancer Institute

To ensure further development of the TCR gene therapy, it is necessary to accurately select TCRs and, at the same time, include strategies that restore or enhance accumulation and activation of T cells in tumors. Here, we present our recent preclinical and translational studies to enhance TCR engineering of adoptive T cells in combination with CAR cell co-stimulation, and, when available, first data of a clinical T cell therapy trial to treat patients with melanoma and head-and-neck cancer (starts in 2018 Q4).

15:05 Introduction to Gamma Delta T Cells and Their Potential for Cancer Immunotherapy

Oliver Nussbaumer, PhD, Head of Cell Research, Cell Research, GammaDeltaT Cels Therapeutics Ltd.

Human tissues contain large numbers of immune cells that play a key role in maintaining tissue integrity, protecting against transformation and infection. Lately, 2019 saw a growing interest in immune cells and response to tissue stress such as cancer, a process called lymphoid stress hypothesis. We have developed methods to investigate the properties of tissue resident γδ T cells, making them available for the first time for clinical development.

15:35 Presentation to be Announced

16:05 Networking Refreshment Break

NEXT-GENERATION T CELL THERAPY

16:30 Novel Targets, Receptors & Cellular Platforms for Cancer Immunotherapy

Mark A. Exley, PhD, Vice President, Cellular Immunology, AgentTus Therapeutics, Inc.

Adoptive cell therapy is making inroads into previously untreatable cancers. However, toxicities along with emerging relapses, high cost of goods, and logistical issues with autologous ACT suggest there is much to do. AgenTus is developing novel tumor target identification, T cell receptor and CAR platforms, and allogeneic cellular delivery systems. A new class of phospho-tumor target receptors, T-cell-based therapies and cell platforms will be described. Clinical trials are planned.

17:00 Joint Methods of Transgene Delivery, CAR Design, Optimization and Target Validation

Thomas Nerreret, PhD, Senior Research Fellow, Internal Medicine II, University Hospital Wuerzburg

While CD19, approved for treatment of several hematologic malignancies, is still by far the best-studied target for CAR T therapy, other candidates are just around the corner, addressing hematologic malignancies that are not susceptible to CD19 targeting. We will hear on these candidates and novel methods of transgene delivery, CAR design, and optimization as well as target validation.

17:30 CRISPR/Cas9 enables the efficient production of allogeneic CAR-T cells engineered to contain multiple genome edits to enhance therapeutic T cell function

Jonathan Turroitt, PhD, Head of Immuno-Oncology, Crispr Therapeutics Inc.

The CRISPR/cas9 system allows for rapid assessment of the consequences of perturbing genes while at the same time deriving potential lead RNAi for cell and gene therapies. This has enabled the optimization of CAR-T cell candidates containing genome edits designed to overcome potential immunological and tumor micro-environment issues. Data for allogeneic CAR Ts targeting leukemias/lymphomas and solid tumors will be discussed.

18:00 Close of Day

RECOMMENDED DINNER SHORT COURSE*

18:30 - 21:30 SC3: Managing the Challenges of Bioassays for Immuno-Oncology

SC4: T Cell Therapies: Current Field, Challenges and Future Directions

• Separate registration required, please see page 3 for details

FRIDAY 22 MARCH

FUTURE TRENDS IN T CELL THERAPY

14:00 Immunotherapy, Target Identification, CAR Design, and Optimization

Mark A. Exley, PhD, Vice President, Cellular Immunology, AgentTus Therapeutics, Inc.

Adoptive cell therapy is making inroads into previously untreatable cancers. However, toxicities along with emerging relapses, high cost of goods, and logistical issues with autologous ACT suggest there is much to do. AgenTus is developing novel tumor target identification, T cell receptor and CAR platforms, and allogeneic cellular delivery systems. A new class of phospho-tumor target receptors, T-cell-based therapies and cell platforms will be described. Clinical trials are planned.

17:00 Joint Methods of Transgene Delivery, CAR Design, Optimization and Target Validation

Thomas Nerreret, PhD, Senior Research Fellow, Internal Medicine II, University Hospital Wuerzburg

While CD19, approved for treatment of several hematologic malignancies, is still by far the best-studied target for CAR T therapy, other candidates are just around the corner, addressing hematologic malignancies that are not susceptible to CD19 targeting. We will hear on these candidates and novel methods of transgene delivery, CAR design, and optimization as well as target validation.

17:30 CRISPR/Cas9 enables the efficient production of allogeneic CAR-T cells engineered to contain multiple genome edits to enhance therapeutic T cell function

Jonathan Turroitt, PhD, Head of Immuno-Oncology, Crispr Therapeutics Inc.

The CRISPR/cas9 system allows for rapid assessment of the consequences of perturbing genes while at the same time deriving potential lead RNAi for cell and gene therapies. This has enabled the optimization of CAR-T cell candidates containing genome edits designed to overcome potential immunological and tumor micro-environment issues. Data for allogeneic CAR Ts targeting leukemias/lymphomas and solid tumors will be discussed.

18:00 Close of Day

RECOMMENDED DINNER SHORT COURSE*

18:30 - 21:30 SC3: Managing the Challenges of Bioassays for Immuno-Oncology

SC4: T Cell Therapies: Current Field, Challenges and Future Directions

• Separate registration required, please see page 3 for details

13:00 Networking Break with Light Snack

THE QUEST FOR OFF-THE-SHELF THERAPEUTIC T CELLS

13:30 Chairperson’s Opening Remarks

Mark A. Exley, PhD, Vice President, Cellular Immunology, AgentTus Therapeutics, Inc.

14:35 Featured Presentation: Non-Gene Edited Approaches to Allogeneic CAR T Cell Therapy

Reggenzeller, PhD, Director, R&D, Cytokine

The ability of the natural killer activator receptor NKG2D to bind eight different ligands that are frequently over-expressed in tumors makes this receptor an attractive candidate for CAR T cell development. Our initial observations of clinical response in patients with relapsed/refractory Acute Myeloid Leukemia after treatment with CYA01, a CAR T cell employing NKG2D for targeting, provides support for the potential for this approach. Our clinical plans to fully explore NKG2D involving CAR T cell therapy that does not involve gene editing methodologies will be discussed.

14:55 Targeting Cytokines to the Tumor Vasculature to Improve the Therapeutic Efficacy of Adoptive T Cell Therapy

Anna Mondino, PhD, Head, Lymphocyte Activation Unit, Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, DBIT

The application of CAR technology may lead to a new paradigm in cancer treatment. Remarkable clinical success has been reached against hematologic malignancies. Physical and functional barriers still limit efficacy against solid tumors. Data supporting the beneficial effects of targeting cytokines that drive tumor vascularisation will be discussed.

15:30 Targeting Cytokines to the Tumor Vasculature to Improve the Therapeutic Efficacy of Adoptive T Cell Therapy

Anna Mondino, PhD, Head, Lymphocyte Activation Unit, Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, DBIT

The application of CAR technology may lead to a new paradigm in cancer treatment. Remarkable clinical success has been reached against hematologic malignancies. Physical and functional barriers still limit efficacy against solid tumors. Data supporting the beneficial effects of targeting cytokines that drive tumor vascularisation will be discussed.

15:30 Targeting Cytokines to the Tumor Vasculature to Improve the Therapeutic Efficacy of Adoptive T Cell Therapy

Anna Mondino, PhD, Head, Lymphocyte Activation Unit, Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, DBIT

The application of CAR technology may lead to a new paradigm in cancer treatment. Remarkable clinical success has been reached against hematologic malignancies. Physical and functional barriers still limit efficacy against solid tumors. Data supporting the beneficial effects of targeting cytokines that drive tumor vascularisation will be discussed.

15:30 Targeting Cytokines to the Tumor Vasculature to Improve the Therapeutic Efficacy of Adoptive T Cell Therapy

Anna Mondino, PhD, Head, Lymphocyte Activation Unit, Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, DBIT

The application of CAR technology may lead to a new paradigm in cancer treatment. Remarkable clinical success has been reached against hematologic malignancies. Physical and functional barriers still limit efficacy against solid tumors. Data supporting the beneficial effects of targeting cytokines that drive tumor vascularisation will be discussed.

15:30 Targeting Cytokines to the Tumor Vasculature to Improve the Therapeutic Efficacy of Adoptive T Cell Therapy

Anna Mondino, PhD, Head, Lymphocyte Activation Unit, Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, DBIT

The application of CAR technology may lead to a new paradigm in cancer treatment. Remarkable clinical success has been reached against hematologic malignancies. Physical and functional barriers still limit efficacy against solid tumors. Data supporting the beneficial effects of targeting cytokines that drive tumor vascularisation will be discussed.
14:00 Chairperson’s Opening Remarks
Catarina Brito, PhD, Lab Head, Animal Cell Technology Unit, IBET

14:05 FEATURED PRESENTATION: Sharpening Preclinical Insight to Improve Clinical Relevance
Sara Colombetti, PhD, Head of Oncology Discovery Pharmacology, Research and Early Development (REDE), Roche Pharma

14:35 3D-3-Culture: A Tool to Unveil Macrophage Plasticity in Tumor Microenvironment
Catarina Brito, PhD, Lab Head, Animal Cell Technology Unit, IBET

15:00 Advanced Human in vitro Models for Preclinical Safety Assessment of Immunomodulatory Drugs
Christina Bertinotti-Laguzzi, PhD, Principal Scientist, Investigative Safety, Roche

15:30 TARGETING TNF-R Family Members: Challenges and Opportunities
Alison Baumgarten, Senior Post-Doc, Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton

16:00 Close of Day
Dinner Short Course Registration

THURSDAY 21 MARCH

12:15 Registration

12:45 Dessert Break in the Exhibit Hall with Poster Viewing

ADVANCED MODELS FOR IMMUNO-ONCOLOGY

14:00 Advanced Preclinical Models of Immuno-Oncology and Translational Strategies in Preparation for the Clinic

14:30 Talks

14:30 Getting Under the Hood - Mass Cytometric Analysis of CAR T Cells in Solid Tumours
Eugene Zhukovsky, PhD, Senior Scientific Director of Immuno-Oncology, Glycotope GmbH

14:45 TARGETED IMMUNOTHERAPY
15:00 Glyco-Optimization of Antibodies Targeting Immune Checkpoint Receptors: Case Studies of an Antagonist and an Agonist
Timo Lischke, Scientist, Preclinical Pharmacology & Cancer Immunology, Glycotope GmbH

15:05 Novel Platforms and Antibody-Based Strategies for Detection of Tumour-Causing Agents and Tumours
Andrew Exley, PhD, Medical Assessor, Biologicals and Biotechnology, Regeneron Pharmaceuticals

15:10 Closer Look at How We Evaluate a New tCell Conjugate in vivo Models for Preclinical Safety
Sara Colombetti, PhD, Head of Oncology Discovery Pharmacology, Research and Early Development (REDE), Roche Pharma

15:30 Novel Approaches for the Evaluation of Anticancer Immunotherapies
Margaret D’Souza, PhD, Immunology Sales Specialist, Sales, ProImmune Ltd.

16:00 Networking Coffee Break

16:30 Therapeutic Combination Benefits of IDO1 Inhibition with T Cell Activation Approaches in Preclinical Models
Mahendra Deonarain, BSc, PhD, CEO and CSO, Antikor Biopharma

16:45 Novel and Translational Strategies
Novel and translational strategies and associated platforms, including sensors, can be leveraged to translate the latest in immuno-oncology research and development to the clinic.

17:00 How Can We Leverage Cutting Edge in vivo Preclinical Models for Cancer Immunotherapy Profiling?
Sara Colombetti, PhD, Head of Oncology Discovery Pharmacology, Research and Early Development (REDE), Roche Pharma

17:30 How Do We Leverage New tCell Models to Probe the Mechanisms of Action of Novel Immunomodulatory Therapeutics?
Margaret D’Souza, PhD, Immunology Sales Specialist, Sales, ProImmune Ltd.

18:00 Close of Day

FRIDAY 22 MARCH

8:00 Morning Coffee

8:30 Chairpersons’ Remarks
Mahendra Deonarain, BSc, PhD, CEO and CSO, Antikor Biopharma

12:00 TCell Dysfunction and Combination Immunotherapy
Dimitris Skokos, PhD, Associate Director, Immunology & Inflammation, Regeneron Pharmaceuticals

12:15 Understanding the Role of NK Cells in Anticancer Immunotherapy
Andrew Exley, PhD, Medical Assessor, Biologicals and Biotechnology, Regeneron Pharmaceuticals

12:30 Networking Refreshment Break with Light Snack
PRESENT A RESEARCH POSTER
Share Your Advancements and Discover the Latest Opportunities in Cancer Research in the Exhibit Hall
Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work at Immuno-Oncology Summit Europe.
To secure a poster board and inclusion in the conference materials, please submit your abstract and coordinate registration by 8 February 2019.
Poster Contributors Receive a £50 Registration Discount!

2018 ATTENDEE DEMOGRAPHICS

COMPANY TYPE
- Biotech/Pharma 75%
- Academic/Government 12%
- Healthcare 8%
- Services 2%
- Financial 2%
- Other 1%

GEOGRAPHIC LOCATION
- UK 31%
- USA 23%
- France 13%
- Germany 6%
- Rest of World 5%
- Belgium 3%
- Sweden 2%
- Rest of Europe 6%
- Asia 6%
- Switzerland 5%

DELEGATE TITLE
- Executive/Director 35%
- Scientist/Technologist 32%
- Sales & Marketing 17%
- Manager 11%
- Professor 4%
- Other 1%

SPONSORSHIP, EXHIBIT & LEAD GENERATION INFORMATION

CHI offers comprehensive sponsorship packages that can be customized to your company’s objectives and budget. Sponsorship allows you to achieve your objectives before, during, and long after the event. Packages may include podium presentations, exhibit space and branding, as well as the use of delegate lists. Signing on early will maximize your exposure to qualified decision-makers and drive traffic to your website in the coming months.

PRESENTATIONS
Available within the Main Agenda!
Showcase your solutions to a guaranteed, targeted audience through a 15- or 30-minute podium presentation during a specific conference program, breakfast, lunch, or separate from the main agenda within a preconference workshop. Package includes exhibit space, on-site branding, and access to cooperative marketing efforts by CHI. For the luncheon option, lunches are delivered to attendees who are already seated in the main session room. Presentations will sell quickly, so sign on early to secure your talk!

INVITATION-ONLY VIP DINNER/HOSPITALITY SUITE
Select specific delegates from the preregistration list to attend a private function at an upscale restaurant or a reception at the hotel. From extending invitations, to venue to suggestions, CHI will deliver your prospects and help you make the most of this invaluable experience.

ONE-ON-ONE MEETINGS
Select your top prospects from the preconference registration list. CHI will reach out to your prospects and arrange the meeting for you. A minimum number of meetings will be guaranteed, depending on your marketing objectives and needs. A very limited number of these packages will be sold.

ADDITIONAL SPONSORSHIP OPPORTUNITIES
Additional Opportunities Available for Sponsorship Include:
- Conference Tote Bags
- Literature Distribution (Tote Bag Insert or Chair Drop)
- Badges/Lanyards
- Program Guide Advertisement
- Padfolios and more...

LOOKING FOR ADDITIONAL WAYS TO DRIVE LEADS TO YOUR SALES TEAM?
CHI’s Lead Generation Programs will help you to obtain more targeted, quality leads throughout the year. We will mine our database of over 1,000,000 life science professionals to meet your specific needs. We guarantee a minimum of 125 leads per program!
Opportunities include:
- White Papers
- Web Symposia
- Custom Market Research Survey
- Podcasts

TO LEARN MORE ABOUT SPONSORSHIP AND EXHIBIT OPPORTUNITIES, PLEASE CONTACT:
Rod Eymael
Manager, Business Development
+1-781-247-6286
reymael@healthtech.com

HOTEL INFORMATION
CONFERENCE VENUE & HOTEL: Hilton London Canary Wharf
Marsh Wall, South Quay, London, E14 9SH, UK. T: 44 (0) 203-002-2300
Discounted Room Rates: £214 Single / £226 Double (includes breakfast and Wi-Fi)
Discounted Room Rate Cut-off Date: 7 February 2019
To make your hotel reservation & for additional travel information, please visit the travel page of Immuno-OncologyEurope.com.

“I liked the up-to-date presentations from academia and pharma, and made new personal contacts during the meeting.”
Armin Sepp, Senior Scientific Investigator, Systems Modeling & Translational Biology, GSK

“Good summary of the latest promising approaches, particularly beyond PD-1 and PD-L1.”
Garrett Keating, Senior Scientist, Adaptimmune

“Great talks; great networking.”
Nicolai Wagtmann, EVP and CSO, Innate Pharma

“Incredible line up of the brightest minds in immuno-oncology.”
Cariad Chester, Analyst, Aquilo Capital Management

“I liked the up-to-date presentations from academia and pharma, and made new personal contacts during the meeting.”
Armin Sepp, Senior Scientific Investigator, Systems Modeling & Translational Biology, GSK

“Good summary of the latest promising approaches, particularly beyond PD-1 and PD-L1.”
Garrett Keating, Senior Scientist, Adaptimmune

“Great talks; great networking.”
Nicolai Wagtmann, EVP and CSO, Innate Pharma

“Incredible line up of the brightest minds in immuno-oncology.”
Cariad Chester, Analyst, Aquilo Capital Management